Introduction
Mycophenolate mofetil (MMF) is a highly effective immunosuppressant that does not adversely affect renal function and has been shown to have a nephroprotective effect in patients with chronic allograft nephropathy [1] . Consequently, MMF has become an integral component of toxicity-sparing regimens that seek to minimize or eliminate exposure to the nephrotoxic calcineurin inhibitors (CNIs).
MMF itself is not pharmacologically active: once MMF is absorbed, it is metabolized to mycophenolic acid (MPA), the major active metabolite. The pharmacokinetics and pharmacodynamics of MMF have been extensively previously reviewed [2] . Briefly, MPA is metabolized primarily to the pharmacologically inactive 7-O-MPA-glucuronide (MPAG), and to other minor metabolites, including the pharmacologically active acyl-glucuronide. MPA is eliminated as MPAG, which is excreted renally. Enterohepatic recirculation takes place; in the gut MPAG is deconjugated back into MPA, which is reabsorbed from the colon, producing a second peak in MPA plasma concentration that contributes to ∼40% of overall MPA exposure.
MPA exposure is correlated with therapeutic efficacy. MPA area under the concentration-time curve (AUC) values between 30 and 60 µg h/mL in the early post-transplant period reduces the risk of acute rejections [3] . When used in combination with cyclosporine in renal transplant recipients, the MPA AUC is correlated conversely with the likelihood of acute rejection [4] . It is therefore important to achieve optimal MPA exposure in order to optimize the transplant outcome. The large inter-and intra-patient variability of exposure to MPA in transplant recipients is not entirely understood, and many factors may also contribute, including race, renal function, albumin level, delayed graft function, concomitantly administered drugs [5] and polymorphisms of metabolic enzymes and multidrug resistance proteins [6, 7] .
When cyclosporine is coadministered with MMF in transplant patients, the plasma concentration or exposure of MPA is reduced [8] [9] [10] [11] [12] and MPAG concentration increased [8, 12, 13] compared with patients receiving MMF plus tacrolimus [8, 9, 13] , or MMF plus sirolimus [10] [11] [12] 14] . The differences in MPA concentration between these regimens have been attributed to the pharmacokinetic interaction between MPA and cyclosporine [11, 12, 15, 16] .
Daclizumab does not appear to interact with MMF or MPA [17] . Although corticosteroids were reported to reduce MPA exposure when given at high dosages (16 mg/day) in one study [18] , a clinically or statistically significant relationship between steroid levels and the pharmacokinetics of MPA could not be demonstrated in another [5] . There are limited published data assessing MPA-sirolimus interactions, and additional studies are needed.
The Symphony study (trial registration: www. clinicaltrials.gov; study number: NCT00231764) compared the safety and efficacy of CNI-sparing regimens with a standard immunosuppression regimen in renal transplant patients [19] . As part of the overall Symphony study, a substudy was carried out to obtain data on the effect of the different immunosuppression regimens on the pharmacokinetics of MMF. In the Symphony study, long-term maintenance levels of calcineurin inhibitors or sirolimus (low doses) from the day of transplantation were compared with standard-dose cyclosporine. Our intention in this substudy was to assess whether these maintenance drug levels from the day of transplantation correlated with MPA exposure. We hypothesized that standard-dose cyclosporine would have the greatest impact on interaction with MPA exposure, low-dose cyclosporine less impact and tacrolimus/sirolimus the least impact.
Methods
This was a pharmacokinetic substudy conducted during the first 3 months of the Symphony study [19] . This substudy was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization-Good Clinical Practice Guidelines (ICH−GCP), and with the local ethical committee or institutional review board approval at each centre. All patients provided written informed consent before inclusion in the study. The criteria for patient selection and treatment allocation for the Symphony study have been described in detail elsewhere [19] .
Pharmacokinetic assessments
Pharmacokinetic data were collected on Day 7, and Months 1 and 3 posttransplant. At each visit, 11 blood samples were collected before the first MMF administration of the day and up to 12 h post-dose [pre-dose (time 0)] and at 20, 40 and 75 min; and 2, 3, 4, 6, 8, 10 and 12 h post-dose. MPA, MPAG and acyl-glucuronide plasma levels were determined using high-performance liquid chromatography with UV detection following as previously described [20] with modification. Free MPA levels were determined using the Centrifree Micropartition R system (Amicon) following the methods of Nowak and Shaw [21] . Analysis of cyclosporine, tacrolimus and sirolimus exposures is referred to as the 'third drug' in this manuscript: whole blood cyclosporine and tacrolimus concentrations were measured using enzyme immunoassay EMIT R methods in a Cobas Mira autoanalyser (Dade-Behring, Palo Alto, CA, USA). Sirolimus levels were determined using high-performance liquid chromatography with tandem mass spectrometry according to the methods described by Brunet et al. [22] . All measurements were performed at the Laboratory of Pharmacology Hospital Clinic, Barcelona, Spain.
Statistical analyses
The primary objective of the pharmacokinetic substudy was to compare the exposure to MPA, MPAG, free MPA (MPA not bound to serum protein) and acyl-glucuronide, measured as the AUC 0-12 , between treatment groups. The secondary objectives were comparison of the effects of cyclosporine, tacrolimus and sirolimus on MPA maximum plasma concentration (C max ), time to C max (T max ) and trough concentration over time, and on the ratio of total MPA to free MPA exposure and the ratio of MPA to MPAG exposure; to find the relationship between selected MPA and MPA metabolite pharmacokinetic parameters at Day 7 and Month 1 with clinical outcomes including biopsy-proven acute rejection (BPAR), gastrointestinal-related adverse events, serum albumin levels and calculated creatinine clearance (using the Cockcroft-Gault formula [23] ) at selected time points; and to find the correlation between MPA and free MPA AUC 0-12 with serum albumin levels and calculated creatinine clearance.
A sample size of 31 evaluable patients [assuming a 25% incidence of non-evaluable patients (defined as profiles with ≥2 adjacent or ≥3 non-adjacent data points missing)] per treatment group was calculated to provide at least 80% power to assure the two-sided significance level of 5% to detect a decrease of 25% in the AUC 0-12 of MPA under cyclosporine treatment. A profile was regarded as non-evaluable and discarded from the analysis if two adjacent or more than two non-adjacent points were missing or if it was considered non-evaluable.
The pharmacokinetic population was defined as all patients who had at least one MPA C max and AUC 0−12 value. The AUC 0-12 was calculated using the linear trapezoidal rule. Pre-dose plasma concentration (C 0 ) and C max were observed; T max was the time point, and C max was observed. All MPAG concentrations were expressed as MPA equivalents. For the analysis of pharmacokinetic interactions between drugs, C max and AUC 0-12 values for MPA and its metabolites, cyclosporine, tacrolimus and sirolimus were normalized by the dosage of the medication taken prior to blood sampling in the following way: Dose-normalized AUC = AUC/morning dose in 100 * mg (cyclosporine)
= AUC/morning dose in mg (tacrolimus and sirolimus).
The same normalization was carried out for C max , unless stated otherwise. Exploratory descriptive statistical analyses were conducted, using a two-sided test with statistical significance declared for P-values <5% (unless otherwise specified). 
Results
A total of 83 patients were enrolled from nine sites in Spain and Belgium; based on prior experience, this sample size was deemed sufficient to address the main question. Patient demographics were broadly similar across the groups at baseline ( Table 1) . The majority of patients were classified as having hypertension (68-94% of patients in each group). By the end of the third month of treatment, 16 patients had withdrawn from the study. Nine patients were withdrawn because of a lack of pharmacokinetic data at Month 3. Among patients with 3-month measurements, withdrawals were a result of poor treatment compliance (four patients) or treatment failure due to discontinuation of assigned study drugs (three patients).
Study drug received
The MMF mean daily dose across the four treatments was 1680-1946 mg over the first 3 months of treatment. The cyclosporine mean daily dose on Day 7 was 425 mg (±133 mg) in the standard-dose group and 236 mg (±58 mg) in the low-dose group, which decreased to 222 mg (±81 mg) and 183 mg (±79 mg), respectively, by Month 3. These doses corresponded to median trough levels by Day 7, Month 1 and Month 3 of 292 ng/mL, 218 ng/mL and 164 ng/ mL for the standard-dose group, and 75.5 ng/mL, 109 ng/ mL and 80.5 ng/mL for the low-dose group, respectively. During the first 3 months, the tacrolimus and sirolimus mean daily doses were 4.3-5.8 mg and 2.9-3.5 mg, respectively (median trough levels by Day 7, Month 1 and Month 3: 8.1 ng/ mL, 7.7 ng/mL and 7.1 ng/mL, and 4.6 ng/mL, 7.5 ng/mL and 7.8 ng/mL, respectively). The mean actual exposure (AUC 0-12 ) to cyclosporine, tacrolimus or sirolimus as appropriate during the first 3 months in the high-dose cyclosporine, low-dose cyclosporine, tacrolimus and sirolimus groups were 4842.3-9230.7 ng h/mL, 2796.2-3601.6 ng h/mL, 129.3-152.3 µg h/mL and 134.1-160.9 µg h/mL, respectively.
MPA and MPAG metabolite pharmacokinetics
Compared with the standard-dose cyclosporine group, values for dose-normalized exposure to MPA were significantly higher for low-dose cyclosporine, low-dose tacrolimus and low-dose sirolimus groups at Day 7; for lowdose tacrolimus and low-dose sirolimus groups at Month 1 and for low-dose sirolimus at Month 3 ( Table 2 ). Patients treated with low-dose tacrolimus or low-dose sirolimus had significantly higher exposure to free MPA compared with standard-dose cyclosporine at Day 7. Compared to the lowdose cyclosporine group, exposure to MPA and free MPA was also significantly greater in the low-dose tacrolimus group at Day 7 and Month 1, and in the low-dose sirolimus group at Month 1. Dose-normalized exposure to MPAG and acyl-glucuronide was significantly lower in patients in the low-dose cyclosporine, low-dose tacrolimus and low-dose sirolimus groups than in the standard-dose cyclosporine group at Month 1, and also at Month 3 for acyl-glucuronide. The difference in exposure to MPAG was also significant at Day 7 for low-dose sirolimus and Month 3 for low-dose tacrolimus (Table 2) .
Compared with the standard-dose cyclosporine group, MPA C max was significantly higher in the low-dose tacrolimus group at Day 7 and Month 1 and in the lowdose sirolimus group at Month 1. MPA trough levels did not differ significantly between the four treatment groups (Table 3) .
There was no correlation between tacrolimus or sirolimus AUC 0-12 and dose-normalized MPA AUC 0-12 or free MPA AUC 0-12 , or between tacrolimus or sirolimus C max and dose- The ratio of MPA to MPAG exposure was significantly higher on Day 7 and Month 1 in patients receiving low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus than in those receiving standard-dose cyclosporine (Table 4) , with differences between the standard-dose cyclosporine group and the low-dose tacrolimus and low-dose sirolimus recipients still observed at Month 3 (all P <0.05 versus standard-dose cyclosporine). In contrast, there were no significant between-group differences in the ratio of MPA to free MPA exposure at any time point (data not shown).
Correlation of MPA and metabolite pharmacokinetics with clinical outcomes
Analyses of the correlation between MPA pharmacokinetic variables and clinical and safety outcomes were conducted 
Clinical outcomes and safety
No BPAR occurred in this 3-month substudy. Mild-tomoderate treatment-emergent gastrointestinal-related adverse events occurring after Day 7 and Month 1 were reported in 10 and 11 patients, respectively, and included diarrhoea, dyspepsia and vomiting. There was no significant relationship between MPA and acyl-glucuronide exposure or acyl-glucuronide C max on Day 7 and Month 1 and the occurrence of gastrointestinal adverse events after 7 days and after 1 month, respectively.
Mild-to-moderate haematological treatment-emergent adverse events occurred in 27 patients during the first 3 months of treatment, including anaemia, leukopenia, lymphadenopathy, nephrogenic anaemia, polycythaemia and thrombocytopenia. One patient suffered from severe leukopenia, which was reported as a serious adverse event.
Discussion
This pharmacokinetic substudy of Symphony was a prospective, longitudinal study with predefined drug target levels, and a relatively high number of patients in comparison with previous studies [8, [10] [11] [12] . Patients received standard-dose cyclosporine, or daclizumab induction plus low-doses of cyclosporine, tacrolimus or sirolimus, all in addition to MMF and corticosteroids; exposure in the first month post-transplant to MPA and free MPA was generally significantly greater in those patients receiving concomitant low-dose tacrolimus or low-dose sirolimus than in those receiving standard-or low-dose cyclosporine. Although it has been suggested that the lower MPA exposure in the cyclosporine groups may contribute to the inferior clinical outcomes relative to the tacrolimus group in the main Symphony study [24] , this is unlikely to be a major factor. For example, the outcomes in the sirolimus group where MPA exposure was similarly raised were discordant with those in the tacrolimus group [19] . Moreover, as the low doses of cyclosporine, tacrolimus and sirolimus retain their distinct and different toxicity profiles, it is likely that the MMF and daclizumab-based regimen containing low-dose tacrolimus and corticosteroids provided the best balance of efficacy and toxicity.
The observation of higher exposure to MPA with tacrolimus compared with cyclosporine is consistent with observations made by other groups [8, 9] including paediatric patients [25] . Similar effects have also been documented when MMF is administered in combination with sirolimus [10] [11] [12] 26] . A similar trend was apparent at Month 3, although not all differences reached statistical significance. Over the 3-month study period, MPA exposure increased markedly in the standard-dose cyclosporine and low-dose sirolimus groups, consistent with the AUC maturation process known to occur with MPA in the early post-transplantation period [27] , but not in the low-dose cyclosporine and low-dose tacrolimus groups.
MPA trough levels have been reported to be higher in patients receiving MMF and tacrolimus [8] or sirolimus [11] than in those receiving MMF and cyclosporine in previous studies, which is consistent with our observations in the early post-transplant period although between-group differences were not significant in our study. In addition, the MPA trough levels were higher in the tacrolimus and sirolimus groups than those in the standard-dose cyclosporine groups by a larger factor than the respective difference between these treatment groups in AUC values. This finding suggests that trough levels cannot be used to estimate change in MPA exposure as expressed by AUC when comparing regimens including cyclosporine to cyclosporine-free regimens. A strong correlation between cyclosporine exposure (AUC 0-12 ) and dose-normalized MPA exposure could not be demonstrated in our study. We would have expected that with a decrease in cyclosporine exposure, dose-normalized MPA exposure would have increased, because a negative correlation between these variables has been previously demonstrated in a study in paediatric renal transplant recipients, where the Pearson correlation coefficient was (r 2 ) 0.2258 (P = 0.0220) [24] . Negative correlations have been reported between cyclosporine C 0 values and MPA C 0 values in two studies in adult patients [9, 13] , although these correlations were significant in only one study, and only between 3 and 6 months post-transplant [9] .
As expected, there was no significant correlation between non-dose-normalized tacrolimus or sirolimus exposure and dose-normalized MPA or free MPA exposure up to 3-month treatment (post hoc analyses). Similarly, there was no significant correlation between pre-dose concentrations of MPA and pre-dose concentrations of tacrolimus [9, 13] or MPA level and tacrolimus trough levels [28] in other studies. Our study results support the current evidence that the differences in MPA exposure between patients receiving MMF plus cyclosporine and MMF plus tacrolimus are attributable to an interaction with cyclosporine [15, 29] , rather than with tacrolimus or sirolimus.
MPAG exposure was higher in the standard-dose cyclosporine group than in the low-dose cyclosporine group (at Month 1). This could explain, in part, the difference in the ratio of MPA exposure to MPAG exposure between the standard-dose and low-dose cyclosporine groups. Dosedependent inhibition of the multidrug resistance protein-2 by cyclosporine [15, 16] may be responsible for these different MPAG levels. The greater ratio of MPA exposure to MPAG in patients receiving MMF plus low-dose tacrolimus versus those receiving MMF plus standard-dose cyclosporine reflects changes in the levels of these metabolites that correspond with changes found in other studies, although whether the higher ratio was due to higher MPA or lower MPAG exposure is not clear. Zucker et al. [8] reported increased MPA and decreased MPAG levels in tacrolimus versus cyclosporine recipients, and Picard et al. [12] reported lower exposure to MPAG in patients receiving sirolimus and MMF than in those receiving cyclosporine and MMF.
The pharmacokinetics of MMF are altered in patients with impaired renal function [3, 5, 30] . We found a negative correlation between renal function and free MPA exposure, which is consistent with another study by Kuypers and others [27] . Exposure to total MPA was not correlated with renal function in our study, in contrast with one study [9] , but in agreement with another study that also investigated the pharmacokinetics of MMF plus a low-dose CNI-based regimen [27] . van Hest et al. have shown that a change in total MPA exposure related to renal function occurs only at creatinine clearance <25 mL/min (0.41 mL/s/1.73 m 2 ) [5] , and more recent results have demonstrated a duality in the effect of renal function on MPA exposure; in patients with moderately impaired renal function, MPA exposure is increased, while in patients with severely impaired renal function MPA clearance is increased, possibly due to an increase in the unbound fraction of MPA, resulting in a decrease in MPA exposure [31] . These studies may explain the divergence of findings between different studies.
We found no significant correlation between MPA or free MPA exposure and serum albumin levels although the range of albumin concentrations observed was rather small and may have precluded seeing a relationship. However, low serum albumin levels have been shown to be associated with a high percentage of free MPA (where percentage free MPA (%) = [free MPA exposure (mg h/L) / total MPA exposure (mg h/L)] ×100) [32] . Total MPA levels [9, 28] or total MPA exposure [5] is positively correlated with serum albumin levels.
The relationship between exposure to MPA and acute rejection is already well accepted [3] , but because no patients in our 3-month substudy experienced an acute rejection, examination of this relationship was not possible.
Previous studies have examined the association between MPA pharmacokinetic parameters and gastrointestinal or haematological adverse events. Different studies have produced contradictory results (reviewed by Staatz and Tett [2] ). MPA has usually been the metabolite of interest in these studies. However, we investigated whether acylglucuronide exposure was predictive of the occurrence of gastrointestinal adverse events. Acyl-glucuronide is of particular interest because it has a proinflammatory effect in leukocytes [33] , which may mediate the gastrointestinal toxicity associated with MMF. We were not able to find any significant correlation between acyl-glucuronide exposure and C max values with the occurrence of gastrointestinal adverse events. These data support another study that examined the relationship between acyl-glucuronide plasma concentration and the incidence of diarrhoea in renal transplant patients receiving MMF and cyclosporine or tacrolimus [34] . We suggest that it could be the concentration of acyl-glucuronide in the intestinal tract that contributes to this adverse effect, as suggested by overall Symphony study results, where the incidence of diarrhoea was highest in recipients of the tacrolimus-containing regimen [19] .
Although our study provides interesting information on the pharmacokinetics of MPA following MMF administration in combination with maintenance levels of calcineurin inhibitors or sirolimus from the day of transplantation, it does have a number of limitations. As our study recruited a relatively small number of patients coupled with the high interindividual variability, the results presented should be interpreted in this context. In addition, since no acute rejection was reported in our study, it is possible that our results may not be applicable to those with acute rejection. Other limitations of our data included that patients recruited were predominantly Caucasian and that they received organs from deceased donors (unpublished data). Consequently, our data may not be generalizable to other transplant practices where there is a high proportion of living donors or where Blacks represent a significant proportion of the transplant population.
In conclusion, compared with recipients of MMF and standard-dose cyclosporine, patients treated with the same dose of MMF and low-dose tacrolimus or lowdose sirolimus had significantly higher MPA and free MPA exposure and lower MPAG and acyl-glucuronide exposure.
